Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
G649309-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$220.90
|
|
|
G649309-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$330.90
|
|
|
G649309-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$660.90
|
|
|
G649309-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,000.90
|
|
|
G649309-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,500.90
|
|
|
G649309-250mg
|
250mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,600.90
|
|
| Specifications & Purity | ≥99% |
|---|---|
| Biochemical and Physiological Mechanisms | GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC 50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC 50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity In Vitro GNE-618 reduces levels of NAD with an EC 50 of 2.6 nM in the NSCLC cell line Calu-6. GNE-618 (10-30 nM; 72 hours) reveals an increase in the sub-2N population and a decreases in the percentage of cells in the G1 and M phases of the cell cycle in Calu-6 cells. GNE-618 also reduces cellular proliferation of Calu-6 cells as determined using two different assay formats, either measuring ATP (EC 50 of 13.6 ± 1.8 nM) or total protein content (SRB assay; EC 50 of 25.8 ± 4.2 nM)MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo GNE-618 (100 mg/kg; p.o.; twice daily for 5 days) significantly inhibits tumor growth by 88% and has minimal effects on body weight in STO#81 patient-derived gastric model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 6 nM (NAMPT) |
| Smiles | O=C(NCC1=CC=C(S(=O)(C2=CC(C(F)(F)F)=CC=C2)=O)C=C1)C3=CC(C=NN4)=C4N=C3 |
|---|---|
| Molecular Weight | 460.43 |
| Solubility | DMSO : 125 mg/mL (271.49 mM; Need ultrasonic) |
|---|